A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Biopôle is a life sciences campus in Lausanne, Switzerland, boasting a renowned community of companies, academic institutions and research organisations, as well as state-of-the-art laboratories, office buildings and amenities. The site is home to more than 120 companies and organisations, including the head offices of multinationals, start-ups, SMEs, clinical development teams and technology and service providers. It also hosts more than 25 world-renowned research groups.
The Office for Economic Affairs and Innovation (SPEI) supports companies that are located in the State of Vaud, especially those involved in the sectors of advanced technology and industry. SPEI advises entrepreneurs and puts them in contact with organizations that are appropriate to their specific needs. SPEI can also provide direct financial support.
Novo Holdings is a holding and investment company, responsible for managing the operating and financial assets of the Novo Nordisk Foundation. Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes and manages an investment portfolio, with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of two teams, namely, Life Science Investments and Novo Capital Investors. We aspire to be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of $106 billion. Novo Holdings is among the world’s leading life science investors and invests in companies at all stages of development. The Life Science Investments team includes Novo Seeds, Novo Ventures, Novo Growth and Principal Investments. In 2021 Life Science Investments invested $2.2 billion in 71 companies. The Novo Capital Investors team manages a broad portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.
For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
M&A (divestments, mergers, acquisitions, and strategic transactions)
Licensing (in and out licensing)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuations (licensing, M&A and fundraising)
Pricing and Market Access
PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Asia-Pacific.
PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).